Neurological disorders are undoubtedly among the most alarming diseases humans might
face. In treatment of neurological disorders, the blood‐brain barrier (BBB) is a challenging …

The treatment of central nervous system disorders, such as Alzheimer's, Parkinson's,
traumatic brain injury, brain cancer, etc. is challenging due to the stringent blood-brain …

For several decades, the treatment of central nervous system (CNS) disorders such as, for
instance, Alzheimer's disease (AD), Huntington's disease (HD), and Parkinson's disease …

Dendrimers have been expected as excellent nanodevices for brain medication. An amine-
terminated polyamidoamine dendrimer (PD), an unmodified plain type of PD, has the …

General aspects: Currently, several strategies have been used to overcome common
problems found in pharmacological therapies, such as insolubility, reduced bioavailability …

Dendrimers have been described as one of the most tunable and therefore potentially
applicable nanoparticles both for diagnostics and therapy. Recently, in order to realize drug …

Aim: Understanding the interactions between nanomaterials and disease processes is
crucial for designing effective therapeutic approaches. This article explores the unusual …

Most of the newly developed drugs fails to achieve sufficient bioavailability in to brain due to
low water solubility and low permeability. Drug delivery systems are one method for …

Treating diseases of the central nervous system (CNS) still remains a problem for the
researchers. Existence of specific anatomical barriers, especially the blood brain barrier …

Polyamidoamine (PAMAM) dendrimers are one of the smallest and most precise
nanomolecules available today, which have promising applications for the treatment of brain …